Avita Medical Inc (ASX:AVH) is a medical technology company focused on advanced wound care solutions. The company operates primarily in the United States market and develops regenerative medicine products designed for wound management. During 2026, Avita Medical reported higher quarterly Revenue and provided updated financial guidance, with investors monitoring progress towards improved operating performance.
Latest Development
Avita Medical reported its second quarter 2026 results in August 2026.
Revenue for the three months ended 30 June 2026 was reported at US$21.7 million, representing growth compared with the prior corresponding period. The company reported a gross Margin of 81.9 per cent for the quarter.
In August 2026, Avita Medical updated its full-year 2026 revenue guidance to a range of US$86 million to US$89 million and maintained its expectation of achieving Cash Flow breakeven in the fourth quarter of 2026.
Company Overview
Avita Medical is a therapeutic acute wound care company focused on regenerative medicine technologies.
Its key product, RECELL, uses a patient’s own skin cells to support treatment of acute wounds, including burn injuries. The company has expanded its product portfolio with solutions including Cohealyx, a collagen dermal matrix, and PermeaDerm, a biosynthetic temporary wound matrix.
Avita Medical operates across international markets and is listed on the Nasdaq under RCEL, while its securities are also traded on the ASX under AVH through CHESS Depositary Interests.
The company continues to focus on commercial adoption of its wound care products, including RECELL and newer product offerings.
Future growth depends on expanding use across healthcare providers, continued product adoption and progress across regulatory and reimbursement pathways.
The company has also highlighted opportunities from expanding its product portfolio and increasing its presence in the advanced wound care market.
What Investors May Watch Next
Investors may continue to monitor quarterly revenue growth, gross margin performance and progress towards the company’s cash flow breakeven target.
Other areas of focus include adoption of RECELL, commercial progress of Cohealyx and PermeaDerm, regulatory developments and expansion across approved markets.
Risks
Avita Medical operates in a healthcare market where adoption cycles can be lengthy and dependent on hospital purchasing processes, reimbursement conditions and regulatory approvals.
The company remains exposed to execution risks associated with commercial expansion, cost management and achieving sustainable cash flow generation. Competition within advanced wound care and currency movements may also influence future results.


_11_13_2026_02_22_23_205137.jpg)



Please wait processing your request...